Nelotanserin
Phase 2Small molecule
Nelotanserin is one of 16 small molecule programs targeting Lewy body dementia. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Lewy Body Dementia
#DrugCompanyPhaseTrials
1Exelon
NovartisApproved
Bosulif
PPrism Pharmaceuticals
Approved
Reminyl
WWim Janssens
Approved
Tasigna
AAzurity Pharmaceuticals
Approved
ACP-204
AACADIA Pharmaceuticals Inc.
Phase 3
Datscan
NNavidea Biopharmaceuticals
Phase 3
Ambroxol Hydrochloride
Boehringer IngelheimPhase 2
LY3154207
Eli LillyPhase 2
Nelotanserin
AAxovant Sciences Ltd.
Phase 2
Donepezil Hydrochloride
EisaiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
REM sleep behavior disorder2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nelotanserin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAxovant Sciences Ltd.